Disease Diagnosis TRIZ Cases

This case uses anti-PAD IgA immunoassays alongside ACPA and RF to improve RA severity and erosive-disease assessment.

This case uses gliadin stimulation and OX40/CD137 detection to diagnose coeliac disease and monitor remission from blood samples.

LDL-associated cFAS capture and antibody detection provide a noninvasive, reliable route to earlier PAD diagnosis.

Specific SULF1 and GALNs antibodies support ELISA or immunoblot detection in urine, blood, and saliva without age or sex parameters.

A micro filter captures fluorescent CD64 cells and PCT polymers for threshold-based sepsis detection and bacterial or viral distinction.

This blood-sample method uses amyloid-binding fluorescence to detect low amyloid levels and monitor inflammation treatment response.

A detectable capture agent quantifies anti-integrin antibodies, guiding plasma exchange until levels reach a predetermined threshold.

Antibody assays detect cystatin B in fluid samples for earlier renal and periodontal diagnosis.

This case combines specific biomarker reagents with an internal synovial-fluid control, targeting accurate diagnosis above 90%.

Specific anti-AS-SPIK antibodies enable standardized biomarker detection and targeted immunoconjugate treatment for liver disorders.

This case uses baseline microvillus length to predict IBD therapy response and avoid sequential trial-and-error treatment.

Villin-1, I-FABP, and α-glutathione S-transferase antibodies enable magnetic extraction for earlier, more specific ischemia diagnosis.

Measure free-to-dissociated PlGF ratios to improve preeclampsia risk detection.

Cytosolic and exosome analyses plus antibody and binding assessments sharpen immunogenicity prediction for personalized cancer vaccines.

This case combines TMAO, cis-aconitate, and valine in urine to improve sensitivity and specificity for metastatic colorectal cancer.

This case uses antibody-based TARC measurement and a threshold to guide canine skin treatment before prolonged trial and error.

Recombinant allergens with mammalian-like glycosylation distinguish allergen-specific IgE from anti-CCD IgE for more accurate diagnoses.

Exosomal biomarker assays support more reliable, non-invasive diagnosis of depression and psychosis.

This case replaces subjective curve assessment with a microprocessor-calculated Ps/Cs ratio for objective FVIII inhibitor screening.

A calculated SLE risk score combines complement and antibody biomarkers to improve diagnosis and track disease activity.

The method uses pre-treatment, post-treatment, and massive-cell-death VOC profiles to evaluate treatment effects in target cell cultures.

Immunofluorescence quantifies CD4 T-cell subsets to track diabetes progression and predict insulin production decline.

Label-free imaging and AI classify tumor phenotypes while preserving living tissue.

NMR-based glycoprotein acetyl measurement broadens circulatory disease risk screening beyond coronary disease and stroke.

A monoclonal antibody targeting type XX collagen's C-terminus enables ELISA detection of PRO-C20 for cancer monitoring.

This assay uses Saposin B capture and immunoprecipitation to measure urinary A2E and assess macular degeneration severity.

This case uses a blood analysis system and D-serine correlation equation to estimate GFR without inulin clearance procedures.

This case uses PIEZO1 agonists and calcium-sensitive fluorochromes in red blood cells to simplify Alzheimer’s risk screening.

This case uses CD51 as a diagnostic and therapeutic target to block TGF-beta production and address immune escape in T-cell malignancies.

This assay combines antigen recognition with rapid Ca2+ flux tracking to quantify T-cell frequency and functional response patterns.

Particle-target complexes settle at a density interface, enabling pathogen isolation, concentration, and analysis within 1–3 hours.

Measuring ETs in EDTA plasma avoids serum artifacts and supports rapid donor organ suitability and graft health assessment.

NOTCH3, HTRA1, endostatin, and IGFBP-1 assays translate small vessel disease signals into earlier diagnosis and prognosis.

Gasdermin E expression identifies IL-1α-producing Th17 cells and supports screening for selective anti-inflammatory compounds.

A unified ST2, IL-6, IL-8, TNFα, and P3NP panel supports NASH diagnosis, prognosis, and progression monitoring from blood samples.

Targeted mass spectrometry measures GD2 and GD3 gangliosides to address CA-125 limits in early-stage ovarian cancer diagnosis.

Physicochemically distinct particles form biomolecule coronas for mass spectrometry and machine learning-based dementia assessment.

This immunoassay approach targets lambda and kappa light chains to reduce heterophil and rheumatoid factor interference.

A peptide microarray uses IgG-switched antibodies as a proxy for complex T cell antigen analysis in heart failure.

Trypsin digestion and targeted mass spectrometry measure EGYR peptide levels despite LARP1 fragmentation in blood samples.

Anti-MUC1* antibodies distinguish cleaved MUC1 from full-length MUC1, improving cancer detection and therapy selection.

Immune-proteomic plasma AAb panels separate lung cancer from benign CT-positive nodules, reducing unnecessary invasive procedures.

Mass cytometry and flow cytometry track pSTAT5 and immune-cell changes in early pregnancy to support earlier preeclampsia intervention.

This immunoassay combines anti-IgM with a free AIM antibody to distinguish free AIM from complex AIM for noninvasive NASH diagnosis.

Protein and metabolite biomarkers, combined with machine learning, support sensitive ischemic stroke detection and severity assessment.

Peptide-loaded HLA Class II antigens help resolve cell-based and bead-based assay discordance for more reliable virtual crossmatching.

Targeted calcineurin inhibitor conjugates treat steroid-resistant inflammation by suppressing Th17 cells while limiting kidney toxicity.

This case uses CDR-defined VHH binding to membrane-proximal EGFR regions, addressing resistance and complex antibody production.

This case uses neutrophil permeabilization and CD64:NE ratio measurement to detect sepsis without flow cytometry.

Anti-BAIB antibody assays measure urine or blood markers to detect kidney damage beyond variable serum creatinine results.